Louis Aronne is a paid consultant and advisory board member for Eli Lilly and Company, the study sponsor and the manufacturer of orforglipron and tirzepatide.
After your gastrointestinal side effects have subsided, then reduce dosing and take one capsule daily
The health risks accompanying obesity are generally well known, and include heart disease, high blood pressure, type 2 diabetes, stroke, certain types of cancer, and a shortened life span
Telangana Cautions on Misuse of Weight-Loss Drug Semaglutide The public has been cautioned against self-medication or purchasing the drug without medical guidance
The GLP-1 pipeline remains active, with seven or more additional approvals expected between 2026 and 2028. As competition increases, pricing dynamics may shift but benefit design, utilization management, and lifestyle modifications will remain essential tools for controlling spend